利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.014 秒)

    Agent for suppression and interception of mailard reaction
    3.
    发明授权
    Agent for suppression and interception of mailard reaction 失效
    抑制和拦截邮寄员反应的代理人

    公开(公告)号：US5352815A

    公开(公告)日：1994-10-04

    申请号：US031997

    申请日：1993-03-16

    申请人： Norihiro Kakimoto ,  Kunie Nakamura

    发明人： Norihiro Kakimoto ,  Kunie Nakamura

    IPC分类号： A61K31/28 ,  A61P3/00 ,  A61P3/08 ,  A61P3/10 ,  A61P43/00 ,  C07B63/04 ,  C07F7/30 ,  C07K14/00

    CPC分类号： C07F7/30 ,  A61K31/28

    摘要： The present invention provides an agent for suppression or interception of the Mailard reaction, which comprises, as the active component, an organogermanium compound represented by formula (1): ##STR1## wherein R.sub.1 to R.sub.3 may be the same or different and each of them represents a hydrogen atom, a lower alkyl group, or a phenyl group; and X represents a hydroxyl group, an O-lower alkyl group, an amino group, or a salt represented by OY (Y is a metal or a basic group-containing compound).Said agent can effectively suppress or intercept the Mailard reaction and has high safety even when administered for a long period of time.

    摘要翻译： 本发明提供了用于抑制或拦截Mailard反应的试剂，其包含作为活性组分的由式（1）表示的有机锗化合物：其中R 1至R 3可以相同或不同， 它们各自表示氢原子，低级烷基或苯基; X表示羟基，O-低级烷基，氨基或OY表示的盐（Y表示金属或含碱性化合物）。 所述试剂可以有效地抑制或拦截Mailard反应，即使在长时间施用时也具有高安全性。

    Agent for preventing and treating opacity of lens
    5.
    发明授权
    Agent for preventing and treating opacity of lens 失效
    防止和处理镜片透明度的代理

    公开(公告)号：US5118679A

    公开(公告)日：1992-06-02

    申请号：US554724

    申请日：1990-07-19

    申请人： Susumu Sato ,  Norihiro Kakimoto ,  Mikio Miyata ,  Shigezo Uga ,  Kunie Nakamura

    发明人： Susumu Sato ,  Norihiro Kakimoto ,  Mikio Miyata ,  Shigezo Uga ,  Kunie Nakamura

    IPC分类号： A61K31/28 ,  A61K31/535 ,  C07F7/30

    CPC分类号： C07F7/30 ,  A61K31/28 ,  A61K31/535 ,  Y10S514/912

    摘要： The present invention is to provide a highly effective agent for preventing and treating opacity of lens, containing the organic germanium compound represented by the fornula (1); ##STR1## (wherein R1 to R3 represent hydrogen atoms, lower alkyl groups each of which may be the same or different and selected from the group consisting of methyl group, ethyl group, etc., or phenyl groups substituted or unsubstituted; X represents a hydroxyl group, an O-lower alkyl group, an amino group or O.sup.- Y.sup.+ {Y represents a metal such as sodium, potassium, etc., or a compound having a basic group such as lysozyme and basic amino acid, etc.})or (2) a combination of the organic germanium compound and aminoguanidien, or (3) a combination of the organic germanium compound specifically defined above and the specific phenoxazine derivative.

    摘要翻译： 本发明提供一种防止和治疗透镜的不透明度的高效试剂，其含有由（1）所表示的有机锗化合物; （1）（其中R 1至R 3表示氢原子，各自可以相同或不同且选自甲基，乙基等的低级烷基或取代或未取代的苯基; X表示羟基，O-低级烷基，氨基或O-Y + {Y表示金属如钠，钾等，或具有碱性基团的化合物如溶菌酶和碱性氨基酸等 ））或（2）有机锗化合物和氨基胍二烯的组合，或（3）上述具体定义的有机锗化合物与特定吩恶嗪衍生物的组合。

    Agent for improving reduced functions of organs caused by inhibited blood circulation
    7.
    发明授权
    Agent for improving reduced functions of organs caused by inhibited blood circulation 失效
    改善由血液循环受阻引起的器官功能降低的药剂

    公开(公告)号：US5006553A

    公开(公告)日：1991-04-09

    申请号：US555829

    申请日：1990-07-23

    申请人： Norihiro Kakimoto ,  Kazuo Kumano ,  Kunie Nakamura

    发明人： Norihiro Kakimoto ,  Kazuo Kumano ,  Kunie Nakamura

    IPC分类号： C07F7/30

    CPC分类号： C07F7/30

    摘要： The present invention provides (1) an agent for improving the reduced functions of organs caused by inhibited blood circulation, characterized by containing, as an effective component, an organogermanium compound represented by the formula (I) ##STR1## wherein R.sub.1 to R.sub.3 are each a hydrogen atom, a lower alkyl group such as methyl, ethyl or the like which may be the same or different, or a substituted or unsubstituted phenyl group, and X is a hydroxyl group, an O-lower alkyl group, an amino group or O.sup.- Y.sup.+ (Y is a metal such as sodium, potassium or the like, or a basic group-containing compound such as lysozyme, basic amino acid or the like), and (2) a method for improving the reduced functions of organs caused by inhibited blood circulation, characterized by administering, in need of such treatment, an effective amount of an organogermanium compound represented by the above formula (I).

    摘要翻译： 本发明提供（1）一种用于改善由抑制血液循环引起的功能降低的药剂，其特征在于，含有式（I）表示的有机锗化合物作为有效成分，其中R1至 R3各自为氢原子，低级烷基如甲基，乙基等可以相同或不同，或取代或未取代的苯基，X为羟基，O-低级烷基， 氨基或O-Y +（Y是金属如钠，钾等，或含碱性基团的化合物如溶菌酶，碱性氨基酸等），和（2）一种改善功能降低的方法 其特征在于，在需要这种治疗的情况下施用有效量的由上述式（I）表示的有机锗化合物。

    Process for isomerization of compound of aldose structure into compound of ketose structure, and isomerization agent or accelerator used therin
    8.
    发明授权
    Process for isomerization of compound of aldose structure into compound of ketose structure, and isomerization agent or accelerator used therin 失效
    醛糖结构化合物异构化为酮糖结构化合物的方法，异构化剂或促进剂

    公开(公告)号：US5877311A

    公开(公告)日：1999-03-02

    申请号：US888285

    申请日：1997-07-03

    申请人： Keiji Umeda ,  Norihiro Kakimoto ,  Takafumi Kasumi

    发明人： Keiji Umeda ,  Norihiro Kakimoto ,  Takafumi Kasumi

    IPC分类号： C07H1/00 ,  C01G17/00

    CPC分类号： C07H1/00

    摘要： A process is provided which comprises isomerizing a compound having a ketose structure by the use of or in the presence of an organogermanium compound having a structural portion represented by formula (I): ##STR1## Due to the use or presence of the organogermanium compound, the process is free from the problems of the prior art, and is capable of isomerizing a compound having an aldose structure into a compound having a ketose structure at a high isomerization ratio without requiring any special apparatus or any complicated operation.

    摘要翻译： 提供了一种方法，其包括通过使用或在具有由式（I）表示的结构部分的有机锗化合物的存在下异构化具有酮糖结构的化合物：（I）由于使用或存在 有机锗化合物，该方法没有现有技术的问题，并且能够将具有醛糖结构的化合物异构化成具有高异构化比例的酮糖结构的化合物，而不需要任何特殊的装置或任何复杂的操作。

    Organogermanium compounds and process for producing the same
    9.
    发明授权
    Organogermanium compounds and process for producing the same 失效
    有机锗化合物及其制备方法

    公开(公告)号：US4977287A

    公开(公告)日：1990-12-11

    申请号：US400062

    申请日：1989-08-29

    申请人： Norihiro Kakimoto ,  Kunie Nakamura ,  Toru Yoshihara

    发明人： Norihiro Kakimoto ,  Kunie Nakamura ,  Toru Yoshihara

    IPC分类号： A61K31/28 ,  A61P3/08 ,  A61P27/02 ,  A61P27/12 ,  A61P43/00 ,  C07F7/30

    CPC分类号： C07F7/30

    摘要： The present invention provides (A) an organogermanium compound represented by the general formula (1) ##STR1## wherein X is a halogen atom and R is a hydrogen atom, a lower alkyl group or a phenyl group, or by the general formula (2) ##STR2## wherein X and Y are each a halogen atom and R is a hydrogen atom, a lower alkyl group or a phenyl group, or by the general formula (3-O), ##STR3## wherein R is a hydrogen atom, a lower alkyl group or a phenyl group, or by the general formula (3-S), ##STR4## wherein R is a hydrogen atom, a lower alkyl group or a phenyl group, or by the general formula (4-O), ##STR5## wherein R is a hydrogen atom, a lower alkyl group or a phenyl group, or by the general formula (4-S), ##STR6## wherein R is a hydrogen atom, a lower alkyl group or a phenyl group, and (B) a process for producing an organogermanium compound represented by each of the formulas (3-O), (3-S), (4-O) and (4-S).

    摘要翻译： 本发明提供（A）由通式（1）表示的有机锗化合物，其中X是卤原子，R是氢原子，低级烷基或苯基，或由通式 式（2）其中X和Y各自为卤素原子，R为氢原子，低级烷基或苯基，或由通式（3-O），（IMA） 3-O），其中R是氢原子，低级烷基或苯基，或通式（3-S），其中R是氢原子，低级烷基 或通式（4-O），其中R是氢原子，低级烷基或苯基，或通式（4-S）的通式（4-O） （3-O），（3）表示的有机锗化合物的制造方法，其中R为氢原子，低级烷基或苯基，（B） -S），（4-O）和（4-S）。

    Resistance imparting agent for cold syndrome of low pulmonary function patients
    10.
    发明授权
    Resistance imparting agent for cold syndrome of low pulmonary function patients 失效
    低肺功能患者感冒综合征耐药机制

    公开(公告)号：US4898882A

    公开(公告)日：1990-02-06

    申请号：US284848

    申请日：1988-12-12

    申请人： Fumio Nagahama ,  Norihiro Kakimoto ,  Kohei Miyao

    发明人： Fumio Nagahama ,  Norihiro Kakimoto ,  Kohei Miyao

    IPC分类号： A61K31/28 ,  A61P11/00 ,  C07F7/30

    CPC分类号： A61K31/28 ,  Y10S514/849

    摘要： Administration of a resistance imparting agent characterized by comprising an organogermanium compound as an effective component shown by the following formula (I); ##STR1## (wherein A and B denote hydrogen or lower alkyl groups such as methyl and ethyl groups, R denotes a combination of one or two atoms or groups shown by A or B, and X denotes an oxygen or nitrogen atom) in patients having low pulmonary function (35 examples of a group to which the agent was administered, 34 examples of an untreated group) showed that the number complaining of cold syndrome was 13 in the first group and 30 in the second group, which the total number of days during which remedies were used by the first group for cold syndrome was 79 days (of a total possible of 4635 days) compared with 295 days (of a total possible of 4860 days) for the untreated group, and that patients having low pulmonary function were apparently endowed with resistance to cold syndrome. Furthermore, no remarkable side-effects were observed.

    摘要翻译： 施用电阻赋予剂，其特征在于，含有下述式（I）所示的有机锗化合物作为有效成分。 （I）（其中A和B表示氢或低级烷基如甲基和乙基，R表示A或B所示的一个或两个原子或基团的组合，X表示氧或氮原子） 在具有低肺功能的患者中（给予该药物的组的35个实例，未处理组的34个实例）显示，冷综合征的数量在第一组中为13，在第二组中为30， 第一组冷综合征使用补救措施的天数为79天（总共4635天），而未治疗组为295天（总共4860天），而且患者为低 肺功能显然具有耐冷综合征。 此外，没有观察到显着的副作用。